This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider.
Felicia Chow, MD: Hello, I'm Dr Felicia Chow. Welcome to Medscape's InDiscussion series on meningitis. Today, we'll discuss what's new in the management of bacterial meningitis with Dr Rodrigo Hasbun. Dr Hasbun is a professor in the division of Infectious Diseases at McGovern Medical School at UTHealth. Welcome to InDiscussion, Rodrigo, it's fantastic to have you on today. I don't think you and I have met before, but I've certainly seen your work and read a lot of your studies, and it's really wonderful to have you on today talking about bacterial meningitis. I was wondering if you could start by talking about how the epidemiology of community-acquired bacterial meningitis has changed in the United States over the past few decades. Are pneumococcal and meningococcal meningitis still the most common causes of community-acquired bacterial meningitis among adults?
Rodrigo Hasbun, MD, MPH: In the last four decades, there's been a shift in the epidemiology of community-acquired bacterial meningitis in the United States. The introduction of the Haemophilus influenzae conjugate vaccinein 1985, and then the
